Immediate Impact

1 from Science/Nature 62 standout
Sub-graph 1 of 24

Citing Papers

Potential Clinical and Economic Impacts of Cutbacks in the President’s Emergency Plan for AIDS Relief Program in South Africa
2025 Standout
A systematic review and meta-analysis of machine learning, deep learning, and ensemble learning approaches in predicting EV charging behavior
2024 Standout
1 intermediate paper

Works of Cecilia L. Moore being referenced

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
2015
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study
2013

Author Peers

Author Last Decade Papers Cites
Cecilia L. Moore 308 249 127 20 429
Elżbieta Bąkowska 304 219 194 18 498
Erica Johnson 333 111 80 19 509
Natascia Sala 315 247 211 12 474
X. de la Tribonnière 255 137 153 33 494
Suzanne Siminski 346 150 104 24 479
Anna Danise 374 287 102 24 492
J. O. Ballard 146 149 41 13 472
David Piontkowsky 416 268 202 27 450
José Cláudio Faulhaber 319 105 135 12 408
M Mannazzu 153 83 192 14 378

All Works

Loading papers...

Rankless by CCL
2026